Contact
Please use this form to send email to PR contact of this press release:
Anthera Pharmaceuticals Announces Completion of Dosing in CHABLIS-SC1 Phase 3 Clinical Study with Blisibimod
TO:
Please use this form to send email to PR contact of this press release:
Anthera Pharmaceuticals Announces Completion of Dosing in CHABLIS-SC1 Phase 3 Clinical Study with Blisibimod
TO: